rasburicase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	4994	134774-45-1

Description:

Molecule	Description
Synonyms: rasburicase fasturtec elitek	a recombinant form of enzyme that degrades uric acid to allantoin just downstream of xanthine oxidase; used to treat hyperuricaemia Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

rasburicase
fasturtec
elitek

a recombinant form of enzyme that degrades uric acid to allantoin just downstream of xanthine oxidase; used to treat hyperuricaemia

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
14	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 23, 2001	EMA
July 12, 2002	FDA	SANOFI SYNTHELABO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tumour lysis syndrome	380.45	34.40	83	2170	8907	63477862
Febrile neutropenia	86.06	34.40	53	2200	118396	63368373
Cytokine release syndrome	80.94	34.40	27	2226	14287	63472482
Hypofibrinogenaemia	73.44	34.40	15	2238	1155	63485614
Methaemoglobinaemia	73.17	34.40	17	2236	2386	63484383
Hyperuricaemia	59.60	34.40	17	2236	5353	63481416
Neutropenia	58.84	34.40	49	2204	174956	63311813
Hyperkalaemia	57.29	34.40	31	2222	54172	63432597
Blood phosphorus increased	49.00	34.40	13	2240	3132	63483637
Subdural hygroma	39.52	34.40	7	2246	250	63486519
Hyperphosphataemia	38.41	34.40	10	2243	2238	63484531
Cardiovascular insufficiency	37.60	34.40	9	2244	1432	63485337
Renal failure	37.52	34.40	32	2221	117620	63369149

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tumour lysis syndrome	568.27	25.53	170	4503	16889	34935369
Methaemoglobinaemia	255.15	25.53	65	4608	3516	34948742
Cytokine release syndrome	119.02	25.53	59	4614	22818	34929440
Thymus hypoplasia	103.61	25.53	21	4652	397	34951861
Lymphoid tissue hypoplasia	103.61	25.53	21	4652	397	34951861
Febrile neutropenia	99.35	25.53	106	4567	136743	34815515
Disseminated aspergillosis	90.56	25.53	21	4652	759	34951499
Haemolytic anaemia	79.16	25.53	35	4638	10444	34941814
Lymphopenia	72.87	25.53	38	4635	16297	34935961
Glucose-6-phosphate dehydrogenase deficiency	59.65	25.53	11	4662	123	34952135
Neutropenia	58.26	25.53	87	4586	156691	34795567
Haemolysis	57.81	25.53	26	4647	8068	34944190
Immune effector cell-associated neurotoxicity syndrome	50.79	25.53	19	4654	3694	34948564
Hyperphosphataemia	47.50	25.53	19	4654	4418	34947840
Cytomegalovirus viraemia	47.19	25.53	22	4651	7408	34944850
Acute kidney injury	42.50	25.53	112	4561	304876	34647382
Hyperkalaemia	38.70	25.53	47	4626	69342	34882916
Chronic lymphocytic leukaemia	38.07	25.53	16	4657	4216	34948042
Clostridium difficile colitis	31.80	25.53	22	4651	15708	34936550
Hypocalcaemia	31.39	25.53	26	4647	24263	34927995
Febrile bone marrow aplasia	30.71	25.53	17	4656	8192	34944066
Bacterial infection	30.18	25.53	22	4651	17041	34935217
Myocardial calcification	29.34	25.53	5	4668	34	34952224
Sepsis	29.29	25.53	67	4606	166494	34785764
Fungal infection	29.22	25.53	21	4652	15914	34936344
SARS-CoV-2 sepsis	29.00	25.53	6	4667	126	34952132
Hyperuricaemia	28.30	25.53	16	4657	8027	34944231
Hyperbilirubinaemia	28.18	25.53	21	4652	16822	34935436
Disseminated intravascular coagulation	27.46	25.53	23	4650	21793	34930465

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tumour lysis syndrome	913.46	23.58	240	6473	23699	79713976
Methaemoglobinaemia	306.67	23.58	75	6638	5482	79732193
Cytokine release syndrome	198.58	23.58	84	6629	35914	79701761
Febrile neutropenia	173.07	23.58	148	6565	230851	79506824
Lymphoid tissue hypoplasia	130.90	23.58	27	6686	903	79736772
Thymus hypoplasia	129.68	23.58	27	6686	946	79736729
Disseminated aspergillosis	125.94	23.58	27	6686	1091	79736584
Haemolytic anaemia	113.11	23.58	46	6667	17774	79719901
Neutropenia	106.79	23.58	126	6587	287584	79450091
Lymphopenia	98.14	23.58	49	6664	30508	79707167
Hyperkalaemia	86.84	23.58	74	6639	114324	79623351
Hyperphosphataemia	79.38	23.58	27	6686	6349	79731326
Hyperuricaemia	69.90	23.58	29	6684	11770	79725905
Acute kidney injury	68.53	23.58	141	6572	519263	79218412
Haemolysis	64.32	23.58	28	6685	12784	79724891
Cytomegalovirus viraemia	64.30	23.58	28	6685	12793	79724882
Glucose-6-phosphate dehydrogenase deficiency	59.88	23.58	12	6701	346	79737329
Immune effector cell-associated neurotoxicity syndrome	58.34	23.58	21	6692	5827	79731848
Blood phosphorus increased	56.50	23.58	24	6689	10323	79727352
Sepsis	51.61	23.58	86	6627	269342	79468333
Disseminated intravascular coagulation	46.65	23.58	32	6681	35810	79701865
Febrile bone marrow aplasia	45.11	23.58	22	6691	12998	79724677
Respiratory failure	44.74	23.58	65	6648	180846	79556829
Bacterial infection	43.26	23.58	29	6684	31251	79706424
Chronic lymphocytic leukaemia	43.07	23.58	16	6697	4850	79732825
Clostridium difficile colitis	42.43	23.58	29	6684	32254	79705421
Hypocalcaemia	41.35	23.58	34	6679	49890	79687785
Thrombocytopenia	40.87	23.58	77	6636	265182	79472493
Fungal infection	37.90	23.58	30	6683	41718	79695957
Blood lactate dehydrogenase increased	35.24	23.58	28	6685	39142	79698533
Cardiovascular insufficiency	34.67	23.58	12	6701	2969	79734706
Blood uric acid increased	33.06	23.58	18	6695	13342	79724333
Encephalopathy	32.61	23.58	34	6679	67363	79670312
Multiple organ dysfunction syndrome	32.35	23.58	45	6668	120201	79617474
SARS-CoV-2 sepsis	31.58	23.58	6	6707	130	79737545
Hypofibrinogenaemia	31.01	23.58	10	6703	1992	79735683
Myocardial calcification	30.61	23.58	5	6708	43	79737632
Renal failure	30.51	23.58	58	6655	200910	79536765
Pseudomonal sepsis	29.38	23.58	13	6700	6161	79731514
Subdural hygroma	28.72	23.58	7	6706	502	79737173
Hypertriglyceridaemia	28.33	23.58	16	6697	12724	79724951
Hypoxia	28.31	23.58	39	6674	103204	79634471
Pyrexia	28.00	23.58	122	6591	678587	79059088
Leukopenia	27.53	23.58	41	6672	116472	79621203
Transverse sinus thrombosis	26.86	23.58	7	6706	658	79737017
Cerebral haematoma	26.26	23.58	13	6700	7929	79729746
Pancytopenia	25.35	23.58	48	6665	165697	79571978
Guillain-Barre syndrome	24.77	23.58	13	6700	8952	79728723
Cytopenia	23.72	23.58	17	6696	20366	79717309
Superior sagittal sinus thrombosis	23.61	23.58	7	6706	1056	79736619

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AF07	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
FDA CS	M0022307	Urate Oxidase
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D006074	Gout Suppressants
FDA EPC	N0000175670	Uric Acid-specific Enzyme

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperuricemia	indication	35885006	DOID:1920

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
08GY9K1EUO	UNII
D05704	KEGG_DRUG
4021376	VUID
N0000148794	NUI
4021376	VANDF
C0937932	UMLSCUI
CHEMBL1201594	ChEMBL_ID
DB00049	DRUGBANK_ID
7851	INN_ID
C469709	MESH_SUPPLEMENTAL_RECORD_UI
7467	IUPHAR_LIGAND_ID
283821	RXNORM
16841	MMSL
44374	MMSL
53180	MMSL
d04805	MMSL
009162	NDDF
134670005	SNOMEDCT_US
395858003	SNOMEDCT_US
415249009	SNOMEDCT_US

Pharmaceutical products:

None